Post-therapeutic relapse of psoriasis associated with CD11a blockade is associated with T cells and inflammatory myeloid DCs

To determine the transcsriptome of skin samples in 4 responding patients who relapsed after receiving efalizumab for treatment of psoriasis, using paired baseline non-lesional (=NL, n=2); lesional (LS, n=4);week 12 post-treatment (week 12, n=4), and relapse (n=4).